Literature DB >> 25112877

p53 is required for cisplatin-induced processing of the mitochondrial fusion protein L-Opa1 that is mediated by the mitochondrial metallopeptidase Oma1 in gynecologic cancers.

Bao Kong1, Qi Wang1, Ella Fung1, Kai Xue2, Benjamin K Tsang3.   

Abstract

Mitochondria are highly dynamic organelles, and mitochondrial fission is a crucial step of apoptosis. Although Oma1 is believed to be responsible for long form Opa1 (L-Opa1) processing during mitochondrial fragmentation, whether and how Oma1 is involved in L-Opa1 processing and participates in the regulation of chemoresistance is unknown. Chemosensitive and chemoresistant ovarian (OVCA) and cervical (CECA) cancer cells were treated with cisplatin (CDDP). Mitochondrial dynamics and protein contents were assessed by immunofluorescence and Western blot, respectively. The requirements of Oma1 and p53 for CDDP-induced L-Opa1 processing, mitochondrial fragmentation, and apoptosis were examined by siRNA or cDNA. CDDP induces L-Opa1 processing and mitochondrial fragmentation in chemosensitive but not in chemoresistant cells. CDDP induced Oma1 40-kDa form increases in OV2008 cells, not in C13* cells. Oma1 knockdown inhibited L-Opa1 processing, mitochondrial fragmentation, and apoptosis. Silencing p53 expression attenuated the effects of CDDP in Oma1 (40 kDa) increase, L-Opa1 processing, mitochondrial fragmentation, and apoptosis in chemosensitive OVCA cells, whereas reconstitution of p53 in p53 mutant or null chemoresistant OVCA cells induced Oma1 (40 kDa) increase, L-Opa1 processing, mitochondrial fragmentation, and apoptosis irrespective of the presence of CDDP. Prohibitin 1 (Phb1) dissociates from Opa1-Phb1 complex and binds phosphorylated p53 (serine 15) in response to CDDP in chemosensitive but not chemoresistant CECA cells. These findings demonstrate that (a) p53 and Oma1 mediate L-Opa1 processing, (b) mitochondrial fragmentation is involved in CDDP-induced apoptosis in OVCA and CECA cells, and (c) dysregulated mitochondrial dynamics may in part be involved in the pathophysiology of CDDP resistance.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Apoptosis; CDDP; Chemoresistance; Mitochondrial Fragmentation; Oma1; Opa1; Ovarian Cancer; Protein-Protein Interaction; p53

Mesh:

Substances:

Year:  2014        PMID: 25112877      PMCID: PMC4175349          DOI: 10.1074/jbc.M114.594812

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  OPA1 alternate splicing uncouples an evolutionary conserved function in mitochondrial fusion from a vertebrate restricted function in apoptosis.

Authors:  A Olichon; G Elachouri; L Baricault; C Delettre; P Belenguer; G Lenaers
Journal:  Cell Death Differ       Date:  2006-10-06       Impact factor: 15.828

2.  Mitotic phosphorylation of dynamin-related GTPase Drp1 participates in mitochondrial fission.

Authors:  Naoko Taguchi; Naotada Ishihara; Akihiro Jofuku; Toshihiko Oka; Katsuyoshi Mihara
Journal:  J Biol Chem       Date:  2007-02-14       Impact factor: 5.157

3.  Fission and selective fusion govern mitochondrial segregation and elimination by autophagy.

Authors:  Gilad Twig; Alvaro Elorza; Anthony J A Molina; Hibo Mohamed; Jakob D Wikstrom; Gil Walzer; Linsey Stiles; Sarah E Haigh; Steve Katz; Guy Las; Joseph Alroy; Min Wu; Bénédicte F Py; Junying Yuan; Jude T Deeney; Barbara E Corkey; Orian S Shirihai
Journal:  EMBO J       Date:  2008-01-17       Impact factor: 11.598

Review 4.  p53 and Nur77/TR3 - transcription factors that directly target mitochondria for cell death induction.

Authors:  U M Moll; N Marchenko; X-K Zhang
Journal:  Oncogene       Date:  2006-08-07       Impact factor: 9.867

5.  Prohibitins control cell proliferation and apoptosis by regulating OPA1-dependent cristae morphogenesis in mitochondria.

Authors:  Carsten Merkwirth; Sascha Dargazanli; Takashi Tatsuta; Stefan Geimer; Beatrix Löwer; F Thomas Wunderlich; Jürgen-Christoph von Kleist-Retzow; Ari Waisman; Benedikt Westermann; Thomas Langer
Journal:  Genes Dev       Date:  2008-02-15       Impact factor: 11.361

6.  Metalloprotease-mediated OPA1 processing is modulated by the mitochondrial membrane potential.

Authors:  Olwenn Guillery; Florence Malka; Thomas Landes; Emmanuelle Guillou; Craig Blackstone; Anne Lombès; Pascale Belenguer; Damien Arnoult; Manuel Rojo
Journal:  Biol Cell       Date:  2008-05       Impact factor: 4.458

7.  Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway.

Authors:  Xiaokui Yang; Michael Fraser; Ute M Moll; Ajoy Basak; Benjamin K Tsang
Journal:  Cancer Res       Date:  2006-03-15       Impact factor: 12.701

8.  Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.

Authors:  Michael Fraser; Tao Bai; Benjamin K Tsang
Journal:  Int J Cancer       Date:  2008-02-01       Impact factor: 7.396

9.  p53's mitochondrial translocation and MOMP action is independent of Puma and Bax and severely disrupts mitochondrial membrane integrity.

Authors:  Sonja Wolff; Susan Erster; Gustavo Palacios; Ute M Moll
Journal:  Cell Res       Date:  2008-07       Impact factor: 25.617

10.  Regulation of the mitochondrial dynamin-like protein Opa1 by proteolytic cleavage.

Authors:  Lorena Griparic; Takayuki Kanazawa; Alexander M van der Bliek
Journal:  J Cell Biol       Date:  2007-08-20       Impact factor: 10.539

View more
  32 in total

Review 1.  New roles for mitochondrial proteases in health, ageing and disease.

Authors:  Pedro M Quirós; Thomas Langer; Carlos López-Otín
Journal:  Nat Rev Mol Cell Biol       Date:  2015-05-13       Impact factor: 94.444

2.  The first direct activity assay for the mitochondrial protease OMA1.

Authors:  Julia Tobacyk; Nirmala Parajuli; Stephen Shrum; John P Crow; Lee Ann MacMillan-Crow
Journal:  Mitochondrion       Date:  2019-03-26       Impact factor: 4.160

Review 3.  Role of the mitochondrial stress response in human cancer progression.

Authors:  Sheng-Fan Wang; Shiuan Chen; Ling-Ming Tseng; Hsin-Chen Lee
Journal:  Exp Biol Med (Maywood)       Date:  2020-04-23

Review 4.  p53 as guardian of the mitochondrial genome.

Authors:  Ji-Hoon Park; Jie Zhuang; Jie Li; Paul M Hwang
Journal:  FEBS Lett       Date:  2016-02-03       Impact factor: 4.124

Review 5.  Recent advances in, and challenges of, designing OMA1 drug screens.

Authors:  Marcel V Alavi
Journal:  Pharmacol Res       Date:  2022-01-07       Impact factor: 7.658

6.  Cystathionine β-synthase regulates mitochondrial morphogenesis in ovarian cancer.

Authors:  Prabir Kumar Chakraborty; Brennah Murphy; Soumyajit Banerjee Mustafi; Anindya Dey; Xunhao Xiong; Geeta Rao; Sarwat Naz; Min Zhang; Da Yang; Danny N Dhanasekaran; Resham Bhattacharya; Priyabrata Mukherjee
Journal:  FASEB J       Date:  2018-03-01       Impact factor: 5.191

Review 7.  The mitochondrial landscape of ovarian cancer: emerging insights.

Authors:  Pallavi Shukla; Keshav K Singh
Journal:  Carcinogenesis       Date:  2021-05-28       Impact factor: 4.944

Review 8.  OMA1-An integral membrane protease?

Authors:  Marcel V Alavi
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2020-10-29       Impact factor: 3.036

Review 9.  Mitochondrial ATP-Dependent Proteases-Biological Function and Potential Anti-Cancer Targets.

Authors:  Yue Feng; Kazem Nouri; Aaron D Schimmer
Journal:  Cancers (Basel)       Date:  2021-04-22       Impact factor: 6.639

Review 10.  Mitochondria: Insights into Crucial Features to Overcome Cancer Chemoresistance.

Authors:  Ilaria Genovese; Marianna Carinci; Lorenzo Modesti; Gianluca Aguiari; Paolo Pinton; Carlotta Giorgi
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.